Compare DBRG & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DBRG | GRDN |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Retail-Drug Stores and Proprietary Stores |
| Sector | Real Estate | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2009 | 2024 |
| Metric | DBRG | GRDN |
|---|---|---|
| Price | $14.29 | $29.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $16.79 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 5.6M | 358.7K |
| Earning Date | 10-30-2025 | 11-10-2025 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.06 | ★ 0.28 |
| Revenue | $100,346,000.00 | ★ $1,389,638,000.00 |
| Revenue This Year | N/A | $19.50 |
| Revenue Next Year | $191.07 | $0.48 |
| P/E Ratio | $131.07 | ★ $106.76 |
| Revenue Growth | N/A | ★ 18.68 |
| 52 Week Low | $6.41 | $17.78 |
| 52 Week High | $14.84 | $37.43 |
| Indicator | DBRG | GRDN |
|---|---|---|
| Relative Strength Index (RSI) | 76.28 | 57.51 |
| Support Level | $9.44 | $28.62 |
| Resistance Level | $9.78 | $29.90 |
| Average True Range (ATR) | 0.66 | 0.94 |
| MACD | 0.40 | -0.05 |
| Stochastic Oscillator | 90.33 | 79.20 |
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.